Targovax ASA: Third quarter 2021 results
Oslo, Norway, 4 November 2021 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2021 results. Targovax’s CEO will give an online presentation and update on the clinical program to investors, analysts and the press at 10:00 CET today (details below).THIRD QUARTER HIGHLIGHTS · Received acceptance of two posters to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November · Presented poster at European Society for Medical Oncology (ESMO)